

Cite this: *Chem. Commun.*, 2019, 55, 12928Received 6th September 2019,
Accepted 3rd October 2019

DOI: 10.1039/c9cc06971b

rsc.li/chemcomm

Site-selective modification of tryptophan and protein tryptophan residues through PdNP bionanohybrid-catalysed C–H activation in aqueous media†

Carlos Perez-Rizquez,^{ib} Olga Abian^{bc} and Jose M. Palomo^{ib}*^a

Herein we report for the first time the site-selective C–H bond arylation of tryptophan and tryptophan residues in proteins in aqueous media at room temperature by using a PdNP bionanohybrid as a heterogeneous catalyst. The reaction proceeds using a stable aryl-diazonium salt without a base.

Tryptophan (Trp) is one of the rarest amino acids present in proteins with a natural abundance of only 1.09%.¹

However, in most cases Trp has a very important role in the biological activity of proteins and especially enzymes, affecting not only activity but also in many cases the selectivity.^{2–6}

Strategies for selective chemical modification of proteins have been well developed in recent years.^{7–15} The selective functionalization of traditional groups such as N-terminal, Lys amino residues, Asp or Glu carboxylic acid residues or side chain cysteines has been successfully employed.^{7–10} However, the established location and number of functionalizable groups on the protein makes this strategy limited, being in most cases a non-specific modification. Thus, new elegant procedures – combining chemical and biological techniques – through C–C strategies (cycloadditions, Staudinger ligation, Michael additions, *etc.*)^{10–15} have been developed for protein site-selective modification. This has allowed modified proteins with enhanced or altered biological properties to be obtained.^{12,13}

Recently, the C(sp²)–H arylation reactions of α -amino acids and peptide-like compounds have attracted attention, especially in the indole unit of tryptophan.^{16–20} Over the years, several protocols with different coupling partners and oxidation systems

were developed for functionalization at the indole C2-position using transition metal catalysis, in which palladium acetate has been the most used catalyst.^{17–22} However, this protocol showed some limitations in the extension to protein modification. The conditions normally require the use of organic solvents, while protein modifications must be performed in water to preserve protein structure, and catalytic performance in enzymes.

Therefore, to overcome all these drawbacks the application of a heterogeneous catalyst that works well in aqueous media would be mandatory. An interesting alternative could be the recently described Pd nanobiohybrids,²³ a heterogeneous metal biohybrid formed by very small dispersed nanoparticles of Pd(0) in a protein network. This catalyst has been successfully applied in C–C bonding or reduction processes.²³

In this work we present for the first time the site-selective modification of tryptophan residues by C–H activation under mild conditions (aqueous media and room temperature) catalyzed by the heterogeneous PdNP biohybrid. The concept was first tested using a protected tryptophan and finally used successfully in the modification of tryptophan residues of a particular enzyme (Fig. 1).

First, the Pd nanoparticle biohybrid (PdNPs-E) was synthesized using the strategy previously described,^{23a} scaling up the synthesis five times. The characterization of the heterogeneous biohybrid was performed, and Pd(0) nanoparticles of around 5 nm diameter size were obtained (Fig. S1, ESI†).

Our studies started by exploring the capacity of this Pd biohybrid as a catalyst in the C–H activation reaction by selective arylation of *N*-acetyl-L-tryptophan methyl ester (**1**) (Table 1).

^a Department of Biocatalysis, Institute of Catalysis (ICP-CSIC), Marie Curie 2, Cantoblanco, Campus UAM, 28049 Madrid, Spain.
E-mail: josempalomo@icp.csic.es

^b Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, 50009, Spain

^c Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, Zaragoza, 50018, Spain

† Electronic supplementary information (ESI) available: Experimental section, characterization data and additional tables and figures. See DOI: 10.1039/c9cc06971b





Fig. 1 Pd biohybrid-catalysed C–H activation of tryptophan in proteins.



Table 1 Optimization of C–H arylation of Trp **1** catalysed by the PdNPs-E biohybrid^a


Entry	Catalyst	Solvent	Time [h]	Conversion ^e [%]
1	Pd(OAc) ₂	EtOAc	16	>99
2	PdNPs-E	EtOAc	16	>99
3	PdNPs-E	Dioxane	16	87
4	PdNPs-E	THF	16	36
5	PdNPs-E	MeOH	2	>99
6	PdNPs-E	MeOH:H ₂ O ^b	2	>99
7	PdNPs-E	MeOH:H ₂ O ^c	2	>99
8	PdNPs-E	EtOH	2	37
9	PdNPs-E	EtOH:H ₂ O ^d	2	70
10	PdNPs-E	EtOH:H ₂ O ^d	2	97
11	PdNPs-E	i-PrOH:H ₂ O ^d	2	75

^a Conditions: **1** (0.192 mmol), **2** (0.192 mmol), solvent (5 mL), catalyst (2 mg), r.t. (ca. 20 °C). ^b (70:30 v/v). ^c (50:50 v/v). ^d (40:60 v/v). ^e Conversion of the product **3** was quantified by HPLC.

The reaction was performed using 4-methoxybenzene-diazonium tetrafluoroborate (**2**), as an electrophilic arylating coupling partner, firstly in ethyl acetate using Pd(OAc)₂ or the PdNPs-E biohybrid as a catalyst. In both cases, >99% of arylated tryptophan **3** was obtained after 16 h incubation. In particular, this result using Pd acetate (5 mol%) is in concordance with reported results.¹⁹

However, our PdNPs-E catalyst showed better performance under these conditions, being at least two times more active.

Among a variety of solvents (Table 1, entries 3–5), an excellent result was obtained in methanol, with full conversion of **1** after 2 h (Table 1, entry 5).

Based on the previous results with PdNPs-E catalysing C–C bonding reaction in aqueous/solvent mixtures,²³ the C–H activation of **1** was performed in a mixture of MeOH/water. The PdNPs-E catalyst showed the same catalytic performance in the mixtures 70/30 or 50/50 (v/v) as in pure methanol (Table 1, entries 6 and 7). Although the full conversion was completed at the same time in pure methanol or aqueous methanol, evaluating the reaction profile we can observe great differences (Fig. S2, ESI[†]). The conversion of **3** was very low (<20%) within 40 min using pure methanol as a reaction medium, while 90% conversion was obtained at that time using the 50/50 mixture (Fig. S2, ESI[†]).

Following these results, other pure or water–mixture alcohols were tested as solvents (Table 1, entries 8–11, Fig. S2b and c, ESI[†]). More hydrophobic alcohols showed lower conversions, although in the case of ethanol, 97% conversion of **3** was achieved in 2 hours using a mixture of 40/60 (v/v) of ethanol/water as a reaction medium (Table 1, entry 10). Isopropanol showed solubility problems of substrates, but the 50/50 mixture with water gave the best results.

Some studies were conducted to evaluate the catalytic results by decreasing the amount of Trp **1** with respect to compound **2**

(Fig. S3, ESI[†]). Performing the reaction in MeOH:water (1:1), similar conversion value of **3** as before was obtained using five times less amount of **1**, while more than 40% decrease in catalytic efficiency of PdNPs-E was obtained using twenty times less of **1**.

These results demonstrate the ability of this Pd nano-biohybrid to perform the C–H arylation reaction under selective and mild conditions.

This heterogeneous catalyst exhibited high stability while maintaining complete activity without loss of Pd after several recycling processes (Fig S4, ESI[†]).


Therefore, after these results we tried to modify tryptophan through this strategy in a more complex environment, such as in a protein structure. Taking into account that the problem of the solubility of **1** did not allow us to reduce the amount of MeOH in the reaction solution, in this case Trp residues are included in the structure of the completely water soluble protein. This could allow us to perform the C–H activation reaction in pure water solution.

As a proof of concept, we selected the lipase from *Candida antarctica B* (renamed as *Pseudozyma antarctica*) (Cal-B) as a model protein. This is a well-known hydrolase, where its crystal structure is solved.²⁴ The protein sequence and tridimensional structure of Cal-B show the presence of five tryptophan groups (Trp52, Trp65, Trp104, Trp113, Trp155) (Fig. S5, ESI[†]). However, only three of them are superficially accessible, two of them on the protein surface (Trp65, Trp155) and another in the oxyanion hole (Trp104) (Fig. S5b, ESI[†]).

The modification of Cal-B with **2** was performed in distilled water (pH~6) at room temperature (Fig. 2). Two different reaction protocols were used for C–H activation of Cal-B Trp residues, modifying the amount of Pd catalyst added, 2 mg or 10 mg of PdNPs-E biohybrid, respectively. After purification, two different modified proteins, Cal-B-T1 and Cal-B-T2 were obtained. Control experiments were also performed, where Cal-B was incubated only in the presence of **2** without a catalyst (protein called Cal-B*) or incubated only in the presence of PdNPs biohybrid without **2** (protein called Cal-B**). Analysis of the different proteins by MALDI-TOF mass spectrometry revealed one Trp modification in the Cal-B-T1 whereas two modifications were obtained in the Cal-B-T2 protein (Fig. 3a).

No modification was observed by MALDI in the Cal-B* and Cal-B** control proteins (Fig. S6, ESI[†]).

Near-circular dichroism (CD) and fluorescence assays were performed on the native and the two modified Cal-B proteins to evaluate the effect of the modifications on the tertiary structure of the protein (Fig. 3b and c). Near-CD spectra show signal loss

**Fig. 2** Site-selective modification of Trp in Cal-B by **2** catalysed by the Pd biohybrid.




Fig. 3 Characterization of the different conjugates Cal-B-T1 and Cal-B-T2. (a) MALDI-TOF spectra, (b) near-UV CD spectra, and (c) fluorescence spectra.

in the Trp area (around 295 nm), stronger in Cal-B-T2 (Fig. 3b). Fluorescence spectra show a shift of the peak in both modified proteins to wavelengths < 330 nm (Fig. 3c), which is related to a less polar environment of Trp.²⁵ Therefore, these structural analyses suggested that the Trp modification alters the tertiary structure of the enzyme.

Trypsin hydrolysis of the different modified proteins was performed to determine which Trp was modified (Fig. S7, ESI[†]). After the hydrolysis, a peptide profile from MALDI-TOF (MS/MS) was obtained for Cal-B, Cal-B-T1 and Cal-B-T2 and clear differences in peptide sequence were found. However, the peptide GTVLGPLDALVSA^PVW^QQTGSALTTALR was found in both modified proteins, which contain Trp155, indicating that Trp155 was not modified although this is a highly exposed amino acid in the Cal-B structure (Fig. 4).

The possible reason why this Trp was not modified could be due to an anion- π interaction²⁶ between Trp155 and Asp145 (Fig. 4b and Fig. S8, ESI[†]).




Fig. 4 (a) Three-dimensional surface structure of Cal-B marking Trp residues exposed on the surface. (b) Representation of the anion- π interaction between Trp155 and Asp145. (c) Representation of the Trp104 and catalytic Ser105. Tryptophan (green), serine (purple). The 3D structure was obtained from the Protein Data Bank (PDB) using Pymol vs 2.0.5. The pdb code for Cal-B is TCA.




Fig. 5 Enzymatic activity of the different conjugate Cal-B proteins against *p*-nitro-phenyl propionate hydrolysis. Cal-B* refers to Cal-B after the reaction only in the presence of **2**, Cal-B** refers to Cal-B after reaction only in the presence of the PdNP biohybrid.

From these results, we can suggest that Trp65 was modified in both Cal-B proteins (Cal-B-T1 and Cal-B-T2). The Trp104 residue is the other that could be more accessible for C-H modification. This amino acid shows an important role in the catalytic activity of this enzyme because it is close to the catalytic serine (Fig. 4c and Fig. S9, ESI[†]); therefore enzymatic hydrolysis of *p*-nitro-phenyl propionate (pNPP) was evaluated with all Cal-B proteins (Fig. 5). Native, control and Cal-B-T1 enzymes showed a similar activity, while the activity of Cal-B-T2 decreased approximately 40% of the initial enzymatic activity (Fig. 5). Also the trypsin digestion of Cal-B-T2 showed a peptide sequence with observed mass of 2808.2366 [$M_{\text{modified Cal-B}} + \text{Na}$] corresponding to the peptide sequence LPVLTW(104)SQ GGLVAQW(113)GLTFFPSIRS including the modification of one Trp residue (Fig. S7, ESI[†]). Therefore, considering all results, we suggest that Trp104 is the second Trp modified in Cal-B-T2.

In conclusion, we have described for the first time the site-selective C-H bond arylation of protected-tryptophan, with the best conditions in an aqueous solution containing methanol, and more interestingly, tryptophan residues in proteins in aqueous media at room temperature by the use of a PdNP biohybrid as a heterogeneous catalyst. It was possible to selectively modify one or two Trp residues in the Cal-B protein by controlling the amount of Pd catalyst used. The structural characterization allowed the identification of the modified Trp in each case. These results open the door to the application of this strategy for the selective and mild modification of biologically relevant proteins.

This work was supported by the Spanish Government the Spanish National Research Council (CSIC), and the Ministry of Education, Youth and Sports of the Community of Madrid and the European Social Fund (PEJD-2017PRE/SAL-3762). The authors thank the European Cooperation in Science and Technology (COST) program under CA15106 grant (CHAOS: CH Activation in Organic Synthesis). The authors also thank Irene Orera and Giuseppe Lattanzio from Proteomics Unit of Servicios Científico Técnicos del CIBA (IACS-Universidad de Zaragoza), ProteoRed ISCIII member, for mass spectra analysis.



Conflicts of interest

There are no conflicts to declare.

Notes and references

- 1 UniProtKB/Swiss-Prot protein knowledgebase release 2019 07 statistics, <http://web.expasy.org/docs/relnotes/relstat.html>.
- 2 V. P. Jaakola, M. T. Griffith, M. A. Hanson, V. Cherezov, E. Y. T. Chien, J. R. Lane, A. P. Ijzerman and R. C. Stevens, *Science*, 2008, **322**, 1211–1217.
- 3 Z. Chen, L. C. Trotman, D. Shaffer, H.-K. Lin, Z. A. Dotan, M. Niki, J. A. Koutcher, H. I. Scher, T. Ludwig, W. Gerald, C. Cordon-Cardo and P. P. Pandolfi, *Nature*, 2005, **436**, 725–730.
- 4 H. Li, S. Ilin, W. Wang, E. M. Duncan, J. Wysocka, C. D. Allis and D. J. Patel, *Nature*, 2006, **442**, 91–95.
- 5 J. M. Watermeyer, W. L. Kröger, H. G. O'Neill, B. T. Sewell and E. D. Sturrock, *Biochem. J.*, 2010, **428**, 67–74.
- 6 M. Miyanokoshi, T. Yokosawa and K. Wakasugi, *J. Biol. Chem.*, 2018, **293**, 8428–8438.
- 7 B. Wu, H. J. Wijma, L. Song, H. J. Rozeboom, C. Poloni, Y. Tian, M. I. Arif, T. Nuijens, P. J. L. M. Quaedflieg, W. Szymanski, B. L. Feringa and D. B. Janssen, *ACS Catal.*, 2016, **6**, 5405–5414.
- 8 J. I. MacDonald, H. K. Munch, T. Moore and M. B. Francis, *Nat. Chem. Biol.*, 2015, **11**, 326–331.
- 9 C. P. R. Hackenberger and D. Schwarzer, *Angew. Chem., Int. Ed.*, 2008, **47**, 10030–10074.
- 10 C. D. Spicer and B. G. Davis, *Nat. Commun.*, 2014, **5**, 4740.
- 11 T. H. Wright, B. J. Bower, J. M. Chalker, G. J. L. Bernardes, R. Wiewiora, W.-L. Nag, R. Raj, S. Faulkner, M. R. J. Vallée, A. Phanumartwiwath, O. D. Coleman, M.-L. Thézénas, M. Khan, S. R. G. Galan, L. Lercher, M. W. Schombs, S. Gerstberger, M. E. Palm-Espling, A. J. Baldwin, B. M. Kessler, T. D. W. Claridge, S. Mohammed and B. G. Davis, *Science*, 2016, **354**, 597.
- 12 A. Díaz-Rodríguez and B. G. Davis, *Curr. Opin. Chem. Biol.*, 2011, **15**, 211–219.
- 13 O. Romero, M. Filice, B. de las Rivas, C. Carrasco-Lopez, J. Klett, A. Morreale, J. A. Hermoso, J. M. Guisan, O. Abian and J. M. Palomo, *Chem. Commun.*, 2012, **72**, 9053–9055.
- 14 B. Bhushan, Y. A. Lin, M. Bak, A. Phanumartwiwath, N. Yang, M. K. Bilyard, T. Tanaka, K. L. Hudson, L. Lercher, M. Stegmann, S. Mohammed and B. G. Davis, *J. Am. Chem. Soc.*, 2018, **140**, 14599.
- 15 M. Filice, O. Romero, J. M. Guisan and J. M. Palomo, *Org. Biomol. Chem.*, 2011, **9**, 5535–5540.
- 16 M. M. Lorion, N. Kaplaneris, J. Son, R. Kuniyil and L. Ackermann, *Angew. Chem., Int. Ed.*, 2019, **58**, 1684–1688.
- 17 A. J. Reay, T. J. Williams and I. J. S. Fairlamb, *Org. Biomol. Chem.*, 2015, **13**, 8298.
- 18 L. Mendive-Tapia, S. Preciado, J. Garcia, R. Ramon, N. Kielland, F. Albericio and R. Lavilla, *Nat. Commun.*, 2015, **6**, 7160.
- 19 A. J. Reay, L. A. Hammarback, J. T. W. Bray, T. Sheridan, D. Turnbull, A. C. Whitwood and I. J. S. Fairlamb, *ACS Catal.*, 2017, **78**, 5174–5179.
- 20 T. Brandhofer and O. García Mancheño, *Eur. J. Org. Chem.*, 2018, 6050–6067.
- 21 Y. Zhu, M. Bauer and L. Ackermann, *Chem. – Eur. J.*, 2015, **21**, 9980.
- 22 S. Preciado, L. Mendive-Tapia, F. Albericio and R. Lavilla, *J. Org. Chem.*, 2013, **78**, 8129.
- 23 (a) M. Filice, M. Marciello, M. P. Morales and J. M. Palomo, *Chem. Commun.*, 2013, **49**, 6876–6878; (b) J. M. Palomo, *Chem. Commun.*, 2019, **55**, 9583–9589.
- 24 J. Uppenberg, M. T. Hansen, S. Patkar and T. A. Jones, *Structure*, 1994, **2**, 293–308.
- 25 J. T. Vivian and P. R. Callis, *Biophys. J.*, 2001, **80**, 2093–2109.
- 26 X. Lucas, A. Bauza, A. Frontera and D. Quiñero, *Chem. Sci.*, 2016, **7**, 1038–1050.

